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Abstract
The Wnt/b-catenin signaling pathway is involved in the normal development of thyroid gland, but its disregulation
provokes the appearance of several types of cancers, including papillary thyroid carcinomas (PTC) which are the most
common thyroid tumours. The follow-up of PTC patients is based on the monitoring of serum thyroglobulin levels which is
regulated by the thyroid transcription factor 1 (TTF-1): a tissue-specific transcription factor essential for the differentiation of
the thyroid. We investigated whether the Wnt/b-catenin pathway might regulate TTF-1 expression in a human PTC model
and examined the molecular mechanisms underlying this regulation. Immunofluorescence analysis, real time RT-PCR and
Western blot studies revealed that TTF-1 as well as the major Wnt pathway components are co-expressed in TPC-1 cells and
human PTC tumours. Knocking-down the Wnt/b-catenin components by siRNAs inhibited both TTF-1 transcript and protein
expression, while mimicking the activation of Wnt signaling by lithium chloride induced TTF-1 gene and protein expression.
Functional promoter studies and ChIP analysis showed that the Wnt/b-catenin pathway exerts its effect by means of the
binding of b-catenin to TCF/LEF transcription factors on the level of an active TCF/LEF response element at [2798, 2792 bp]
in TTF-1 promoter. In conclusion, we demonstrated that the Wnt/b-catenin pathway is a direct and forward driver of the
TTF-1 expression. The localization of TCF-4 and TTF-1 in the same area of PTC tissues might be of clinical relevance, and
justifies further examination of these factors in the papillary thyroid cancers follow-up.
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Introduction
Papillary thyroid carcinoma (PTC) is the most common thyroid
cancer representing about 80% of all thyroid cancers [1].
Treatment of PTC is based on total thyroidectomy and
radioiodine therapy [2]. The gold-standard method in the
follow-up of patients after surgery/radioiodine is based on
monitoring of serum thyroglobulin (Tg) levels, which showed a
higher sensitivity than cytology for the detection of cervical lymph
node metastasis [3]. However, the thyroid specific transcription
factor TTF-1 regulates Tg expression by binding to its promoter
[4]. Therefore, TTF-1 is considered with Tg as the most important
markers for follicular cells [5,6].
The transcriptional factor TTF-1 (also known as NKX2-1, T/
EBP or TITF-1) is commonly expressed in the thyroid gland, lung
and central nervous system [7]. It is considered as a marker of
differentiation in thyroid and lung carcinoma [8] and has been
widely used to discern the primary site of thyroid and lung tumour
origininpatientswithmetastatic disease [9,10,11,12].Inthe thyroid
gland, TTF-1 is expressed in the follicular cells and, together with
Pax8, controls the expression of Tg, thyroperoxydase (TPO),
thyrotropin receptor (TSH), the sodium/iodide symporter (NIS)
and calcitonin and major histocompatibility complex class I genes.
Consequently, the combination of these two factors plays a role in
the expression of the thyroid-specific phenotype. TTF-1 mRNA is
detected in papillary carcinomas (PTC) but not in anaplastic
carcinomas; therefore TTF-1 is considered as a marker to
distinguish between these two types of thyroid neoplasms [13,14].
Concerning the prognosis, TTF-1 expression may be increased in
PTC with aggressive clinical course [15].
The Wnt signaling pathway is a complex network of proteins
described to be involved in the control of thyrocyte proliferation
[16] and to play a pivotal role in thyroid cancer development [16].
In the absence of Wnt signal, b-catenin is targeted for degradation
in the proteasome. In the presence of Wnt ligands, the Frizzled
receptor is activated, leading to the repression of GSK3b and
consequently to the accumulation of b-catenin and its transloca-
tion to the nucleus [17]. There, b-catenin forms a complex with
the nuclear transcriptional regulator T-cell factor/lymphoid
enhancer factor (TCF/LEF), to promote the expression of Wnt
target genes [17]. For examples in normal thyroid tissue, Wnt-1
ligand enhances cell growth of differentiated thyroid cell and
regulates thyroperoxidase gene, a critical enzyme for thyroid
hormone synthesis in thyrocytes [18] and GSK3b are tightly
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activation of the Wnt signaling pathway may be a common
denominator for the development of tumours [20] and strongly
involved in thyroid tumorigenesis [21]. It was reported a dominant
role of Wnt/b-catenin signaling relative to the TSH/PKA/CREB
pathway in the proliferation of normal and neoplastic thyrocytes
[22]. Also, aberrant b-catenin expression or localisation are often
described to be associated with the more aggressive behaviour in
PTCs [22–23] and many b-catenin target genes have been shown
to play an important role in cancer progression including c-myc,
cyclin D1, matrix metalloproteases, CD44 and homeodomain-
containing genes [24,25,26,27,28]. Furthermore, it has also been
suggested that b-catenin may play a direct role in the
dedifferentiation of the late-stage disease of PTC [16,29].
The role of Wnt/b-catenin signaling in TTF-1 regulation
remains unclear. The aim of this study is to investigate whether the
Wnt/b-catenin pathway could regulate TTF-1 expression in a
papillary thyroid carcinoma model and to examine the mecha-
nism(s) involved in this regulation. We show herein that Wnt/b-
catenin pathway is a direct driver of TTF-1 expression.
Results
The major components of the Wnt/b-catenin signaling
pathway and TTF-1 are co-expressed in the TPC-1 cell line
and papillary thyroid carcinomas
We investigated by real-time PCR the relative expression in the
TPC-1 cell line of TTF-1 as well as the major components of the
Wnt/b-catenin pathway (Wnt1 ligand, the negative regulator
Dickkopf (Dkk1), the LRP6 co-receptor, Dishevelled (Dsh1-2-3), b-
catenin and the transcription factors: LEF-1, TCF-1, TCF-3,
TCF-4. Most of these genes were less expressed 300-fold to 3-fold
than RPL13A, except for Dsh3 (1.2-fold higher than RPL13A)
and b-catenin (4.8-fold higher than RPL13A) (Figure 1A).
Immunocytochemistry (ICC) experiments were performed to
determine the presence and the subcellular localization of Wnt/b-
catenin signaling pathway and of TTF-1 protein in the human
TPC-1 cells. As depicted in Figure 1B, GSK-3b staining was
strictly cytoplasmic, while b-catenin exhibited both nuclear and
cytoplasmic localization. TCF/LEF1, TCF3-4 and TTF-1 pro-
teins were strictly nuclear. Moreover, TCF-4 and TTF-1 were co-
localized in the nuclei of TPC-1 cells (Figure 1C). Interestingly,
immunohistochemical studies performed on four papillary thyroid
carcinomas and three normal thyroid tissues taken at distance of
benign adenoma showed a TCF-4 and TTF-1 positive expression
and localized in nuclei in normal tissue as well as in PTC.
Immunostains performed on consecutive serial histological
sections showed that both TCF-4 and TTF-1 are expressed in
the same areas within tumours (Figure 1D).
Altogether, our results clearly showed that the major compo-
nents of Wnt/b-catenin signaling pathway as well as TTF-1 are
expressed in TPC-1 cells. Thus, we aimed to explore the potential
regulation of TTF-1 expression by Wnt/b-catenin pathway.
LRP6, Dsh, b-catenin and TCF are required for the basal
expression of TTF-1 gene
To investigate whether Wnt/b-catenin pathway controls the
expression of TTF-1, we knocked-down the expression of the
Wnt/b-catenin pathway major components: LRP6, b-catenin,
LEF1 and TCF-4. LRP6, b-catenin, LEF1 and TCF-4 knockdown
by siRNAs led to a reduction in their cognate mRNA levels by
280% 295% demonstrating the efficiency of the knockdown
(Figure 2A). The silencing of Wnt pathway components potently
reduced TTF-1 mRNA (Figure 2B) and protein levels (Figure 2C).
To assess if the effect of Wnt/b-catenin is exerted on the level of
TTF-1 promoter, we transfected TPC-1 cells with a luciferase
reporter plasmid baring 2.11 kbp of TTF-1 promoter, with
plasmids expressing dominant negative forms of either LRP6
(LRP6Dn), Dsh (DEPXDn), b-catenin (b-cateninDn) or TCF
(TCFDn). The efficiency of the knockdown of Wnt/b-catenin
pathway was tested on TOP-Flash-Luc construct that contains four
copies of TCF/LEF response element. TOP-Flash-Luc transcrip-
tional activity was strongly inhibited when the dominant negative
forms of Wnt components were overexpressed (up to 95%
inhibition) (Figure 2D, left panel). TTF-1 promoter activity was
decreasedby80%whenLRP6Dnwastransfected,and by95%with
the DEPXDn, b-cateninDn and TCFDn (Figure 2D, right panel).
These results demonstrate that the Wnt/b-catenin signaling
pathway is crucial for the basal expression of the TTF-1 gene.
The stabilization of b-catenin induces TTF-1 expression
We then determined whether b-catenin stabilization may
further increase TTF-1 gene expression. To mimic Wnt/b-catenin
activation, we stabilized b-catenin by treating TPC-1 cells with a
GSK-3b inhibitor: LiCl (1, 5, 10, 20 mM), for 10 min, 24 h and
48 h. We observed a 10-fold increase in the expression of TTF-1
at 24 h when cells were incubated with 5 to 20 mM LiCl
(Figure 3A). This up-regulation was maintained at 48 h for all the
concentrations of LiCl tested. We also observed an increase of
TTF-1 mRNA expression even with 1 mM LiCl concentration.
Western blot analysis at 24 h confirmed the stimulation of TTF-1
at the protein level. The enhancement of TTF-1 expression was
concomitant with an increase of b-catenin protein level (Figure 3B).
LiCl induces b-catenin recruitment on TCF/LEF binding
site in the TTF-1 promoter
To pinpoint the effects of b-catenin stabilization at the level of
the TTF-1 gene promoter, we adopted two strategies: (i) functional
deletion of TTF-1 promoter, (ii) ChIP analysis of the recruitment
of b-catenin on the level of TTF-1 promoter.
First, the effect of LiCl on the regulation of TTF-1 transcription
was investigated by transfecting TPC-1 cells with a reporter
plasmid coupled to different fragments of the TTF-1 promoter
(Figure 4A). TOP-Flash-Luc and FOP-Flash-Luc (the TCF/LEF
sites were inactivated by point-mutations) were used as positive
and negative controls, respectively. Cells transfected with the
TTF-1 promoter fragments [TTF-1 Luc-2.84, TTF-1 Luc-2.11,
TTF-1 Luc-0.95] as well as TOP-Flash-Luc displayed approxi-
mately a 2-fold increase in luciferase reporter activity after
incubation with LiCl as compared to untreated cells. The
luciferase activities were not enhanced by LiCl in the cells
transfected with the smaller promoter fragment [TTF-1 Luc-0.21],
the empty vector (pSV0A-Ldelta59) or the FOP-Flash-Luc. These
results suggest the presence of a TCF/LEF responsive element
between 0.95 and 0.21 kbp upstream of the transcription start site
which could be responsible for the TTF-1 up-regulation by LiCl.
In silico analysis of the TTF-1 promoter sequence up to
22840 bp from the ATG (available in the human genome database
Ensembl) revealed by Genomatix software the presence of two
putative binding sites for TCF/LEF (Figure 4B). The first one
corresponds to the P1 location [2798, 2792 bp] while the second
one is located between [21997, 21991 bp] and here referred to as
P2. To verify the effective recruitment of b-catenin on the putative
TCF/LEF binding sites, we conducted three ChIPassays on TPC-1
cell extracts treated with LiCl (10 mM for 1H and 4H). A 2-fold
stimulation of b-catenin recruitment was observed after 1H and 4H
of LiCl but only for the P1 site (Figure 4C). The P2 site [21997,
21991 bp] did not further recruit b-catenin. These results indicate
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transcriptional activation by TCF/b-catenin complex.
Discussion
TTF-1 plays a very important role in the development, cell
growth and differentiation process of thyroid. TTF-1 is expressed in
thyrocytes where it regulates the activity of specific genes related to
thethyroidfunction.Inneoplastictissues,TTF-1isused asa marker
of differentiation in thyroid and lung carcinomas [8] and has been
widely used to discern the primary site of thyroid and lung tumour
origin in patients with metastatic disease [9,10,11,12]. Importantly,
TTF-1isexpressedatlowerlevelsinmalignantthyroidascompared
with normal thyroid tissue and is also used as marker of thyroid
differentiation [13]. It has been suggested that normal expression of
Wnt/b-cateninsignaling pathway have a functional relevanceinthe
control of thyrocyte proliferation [22] and its dysregulation
represents a key step in neoplastic thyrocyte proliferation
[21,29,30]. The study of the cross-talk between Wnt/b-catenin
pathway and TTF-1 is of great interest to understand the normal
development of thyroid and its transformation into carcinoma.
Therefore, we investigated whether the Wnt/b-catenin pathway
regulates TTF-1 expression in a human PTC model (TPC-1) and
examined the inherent mechanism(s).
First, we verified the TTF-1 expression in the human TPC-1
cell line and in human papillary thyroid carcinoma by qRT-PCR
and immunofluorescence. In both cases, we showed the nuclear
localization of the TTF-1 protein. We started with these
experiments because several authors failed to find a TTF-1
expression in TPC-1 cells [31,32,33]. While, in contrast, others
reported its presence in the same cell line [34,35]. The discrepancy
between these reports might be explained by the emergence of
novel strains of cell lines due to self-selection or mutations, as
suggested by Pilli et al., [36] or to technical problems due to the
sensitivity of the techniques used for the detection.
Figure 1. Co-expression of Wnt/b-catenin pathway components and TTF-1 in the TPC-1 cell line and PTCs. (A) TPC-1 cells were cultured
for 24 h, total RNA was isolated, reverse transcription was performed and then cDNA was amplified by real time PCR (qRT-PCR) using primers
described in Table 1. Results were compared to RPL13A expression. Data are represented as the mean of three independent experiments. (B) TPC-1
cells were incubated for 24 h, fixed and immunostained for GSK3-b, b-catenin, TCF/LEF1, TCF3-4 and TTF-1 with primary antibodies and Alexa 555 or
488-conjugated secondary antibodies. Cell nuclei were stained with TO-PRO3 iodide (blue) and fluorescence was assessed by fluorescence
microscopy combined with confocal analysis. Representative images of three independent experiments are shown with magnification, 660. (C) The
expression assessment and localization of TCF-4 and TTF-1 in TPC-1 cells performed by immunocytochemical studies. TTF-1 antibody conjugated with
Alexa fluor 488 (red) or TCF-4 antibody conjugated to Alexa fluor 555 (green) were used, cell nuclei were stained with TO-PRO3 iodide (blue).
Fluorescence was assessed by fluorescence microscopy combined with confocal analysis (representative images of three independent experiments).
(D) Immunohistochemistry experiments were carried on paraffin-embedded in papillary thyroid carcinomas (1 and 2) and in normal thyroid tissues (5
and 6) using the antibodies recognizing either TTF-1 or TCF-4, magnification6100. Consecutive serial sections (6400) were performed for PTC tissues
(3 and 4). The high power view of papillary structures corresponds to the red square on the lower magnification (6100).
doi:10.1371/journal.pone.0022280.g001
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in our study are expressed and their proteins localized in TPC-1
cells. We then investigated whether the Wnt/b-catenin pathway
regulates TTF-1 and two strategies were adopted.
The first one consists of knocking-down the molecular
compounds of Wnt/b-catenin upstream (LRP6, Dsh) or down-
stream (TCF-4) of the b-catenin. We found a downregulation of
TTF-1 mRNA and protein. The loss-of-function experiments
revealed a strong inhibition of the transcriptional TTF-1 activity
with dominant negative LRP6, Dsh, b-catenin and TCF
expression vectors. Taking together, these findings confirm that
the molecular partners of Wnt/b-catenin are responsible for the
TTF-1 regulation by post-transcriptional effects influencing the
TTF-1 mRNA and protein expression and that they are required
for the basal expression of the TTF-1 promoter.
The second strategy consists of mimicking the effects of Wnt
signaling activation through GSK-3b inhibition by LiCl [37,38].
An up-regulation of TTF-1 mRNA and protein was observed.
Moreover, promoter studies indicated the presence of putative
binding sites for TCF/LEF between 0.95 and 0.21 kbp upstream
the ATG responsible of the LiCl effect. Indeed, ChIP experiments
demonstrated that the TCF/LEF responsive element [2798;
2792] is responsible for LiCl-induced b-catenin recruitment on
TCF/LEF binding site in the TTF-1 promoter.
Inconclusion,the presentstudyhasa doubleimpact.First,from a
fundamental point of view, this work demonstrates for the first time
that Wnt/b-catenin regulates TTF-1 in papillary thyroid cancer
cells through b-catenin-binding to a TCF/LEF-responsive element
present in TTF-1 promoter. This will influence TTF-1 mRNA and
protein expression. We suggest that Wnt/b-catenin pathway
contributes to the fine-tuning of TTF-1 expression and could have
different biological consequences according to the cellular context.
We speculate that a normal Wnt/b-catenin expression maintains
the basal expression of TTF-1 expression and a differentiated cell
state, whereas activation of Wnt/b-catenin signaling would have an
effect on tumour progression (occurs consequently to mutations
within the molecular Wnt signalingpartners leadingto a continuous
activation of b-catenin and thus of TTF-1) or tumour regression
Figure 2. Silencing of Wnt components reduces TTF-1 levels and required for the basal expression of TTF-1. A, B and C: TPC-1 cells
were transfected with 50 nM of siRNAs targeting LRP6, b-catenin, LEF1 or TCF-4, and a non-targeting siRNA sequence (siNT) as control. mRNA
expression of LRP6, b-catenin, LEF1, TCF4 (A) and TTF-1 (B) were analyzed by real-time PCR and normalized to RPL13A mRNA, then recorded as the fold
change compared to the non targeting siRNA (siNT). A. Significant inhibition of LRP6, b-catenin, LEF1 and TCF4 was found for cells transfected with
siRNAs targeting the corresponding genes compared with those transfected with the scrambled sequence. (B) Significant inhibition of TTF-1 in cells
transfected with siRNAs targeting LRP6, b-catenin, LEF1 or TCF-4. (C) Western blot data showing the effect of siRNAs targeting LRP6, b-catenin, LEF1
and TCF-4 on TTF-1 protein expression, b-actin was used as internal control (images from one experiment representative of three independent
experiments) (D) TPC-1 cells were co-transfected with TOP-Flash-Luc vectors or with the TTF-1-luc-2.11 and dominant-negative plasmids (LRP6Dn,
DEPXDn, b-cateninDn, TCFDn) and luciferase activity was assessed 24 h later. Results were expressed as percent of transcriptional activity as
described in Material and Methods section. Columns represent three independent experiments and bar the standard deviation of the mean.
doi:10.1371/journal.pone.0022280.g002
TTF-1 Regulation by Wnt/b-Catenin Pathway
PLoS ONE | www.plosone.org 4 July 2011 | Volume 6 | Issue 7 | e22280(through inactivation of GSK-3b by chemical molecules such as
LiCl leading to moderate TTF-1 activation).
From the medical point of view, inactivation of GSK-3b by
LiCl alone [39] or in combination with HDACi [40] was found to
be sufficient to inhibit growth in medullary thyroid cancer cells.
We hope that the administration of LiCl or other GSK-3b
inhibitors or Wnt modulators will stimulate the expression of
TTF-1 and, as a consequence, promotes thyroid cells differen-
tiation in pathologies where TTF-1 expression is weak or lacking.
This is of great interest for thyroid or lung cancers where TTF-1
expression is crucial to maintain cell differentiation. Finally, the
localization of TCF-4 and TTF-1 in the same area of PTC tissues
might also be of clinical interest, and justifies further examination
of these factors in the follow-up of papillary thyroid cancer.
Knowing that, TTF-1 is a tissue specific transcription factor, the
relevance of this observation could also be investigated in tissues
where TTF-1 is also expressed such as the lung and the
diencephalon.
Materials and Methods
Ethics Statement
The study was approved by the Ethical Committee of the
Institut Gustave Roussy. Patients gave written informed consent.
No industry gave support for this study.
Cell line
The human TPC-1 cell line was kindly provided by Dr. C.
Dupuy (FRE2939 CNRS, IGR, France). The cell line was grown
in Dulbecco’s Modified Eagle Medium (DMEM) (Invitrogen,
Cergy-Pontoise, France) supplemented with 10% fetal bovine
serum (FBS), 100 units/ml penicillin and 100 mg/ml streptomycin
(Invitrogen). Cells were incubated at 37uC in a humidified
atmosphere containing 5% CO2.
Immunocytochemistry
TPC-1 cells were plated in 6-well plates with coverslide at a
density of 2610
4 cells per well. The protocol used in this study was
as previously described [41]. The following primary antibodies
were used: rabbit polyclonal anti-b-catenin (1:100, Sigma, France),
rabbit polyclonal anti-GSK-3b (1:100, Millipore, France), mouse
monoclonal anti- TCF/LEF-1 (1:100, Millipore, France), mouse
monoclonal anti-TCF3-4 (1:100, Abcam, USA), mouse monoclo-
nal TCF-4 (1:100, Millipore, France) and rabbit polyclonal anti-
TTF-1 (1:100, Upstate, USA). Cells were labeled with conjugated
antibodies (Alexa fluor 555 or 488, Invitrogen, France) for 1 h in
the dark in a humidified chamber and nuclei of cells were detected
with TO-PRO3 Iodide (Invitrogen, France). After final washes,
the coverslips were mounted on slide using Fluoromount-G
(SouthernBiotech, USA) and cells were analyzed with a Zeiss
LSM 510 confocal microscope.
Figure 3. LiCl induces TTF-1 expression. (A) TPC-1 cells were incubated without or with 1 mM, 5 mM, 10 mM, and 20 mM of LiCl for 10 min,
24 h and 48 h. Expression of TTF-1 mRNA was quantified by real-time PCR and normalized with RPL13A mRNA. Results of three independent
experiments are reported as mean and standard deviation of the mean (SD). a: significant changes between cells cultured for 10 min and 24 h and
48 h. b: statistical significance between cells cultured for 24 h and 48 h. (B) TTF-1, b-catenin and b-actin protein levels in cells incubated for 24 h with
the same LiCl concentrations; Western blot experiments were performed three times.
doi:10.1371/journal.pone.0022280.g003
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Human thyroid tissues embedded in paraffin blocks were
obtained from archive files of Institut Gustave-Roussy, pathology
department. They included four primary papillary carcinoma and
three apparently normal thyroid tissues taken at distance of benign
adenoma. An immunohistochemical study was done on freshly cut
4-mm serial sections with anti-TTF1 (Upstate) and anti-TCF4
(Millipore). Immune complexes were visualized using HRP anti-
Rabbit (DAKO- Carpinteria, ref: K 4011) and DAB chromogen
solution (DAKO, ref. K 3468). Nuclei were lightly counterstained
with hematoxylin and sections were mounted with Histomount
(National Diagnostics).
Plasmids, siRNAs and Chemicals
Firefly luciferase reporter plasmids containing various regions of
the TTF-1 promoter (TTF-1-luc-2.84, TTF-1-luc-2.11, TTF-1-
luc-0.95, TTF-1-luc-0.21) and the control empty vector (pSV0AL-
A(delta)59) were used as previously described [42]. TOP-Flash-luc,
FOP-Flash-luc plasmids and PCS2+ vectors carrying cDNA
fragments encoding dominant-negative form of LRP6 (LRP6Dn)
[43], of Dishevelled (DEPXDn), of b-catenin (b-cateninDn) and of
TCF (TCFDn) were kindly provided by Dr C. Fonte (UMR788,
Inserm le Kremlin-Bice ˆtre, France). LRP6, b-catenin (CTNNB1),
LEF1 and TCF-4 (TCF7L2) SMARTpool ON-TARGET-plus
siRNAs and non-targeting siRNA (NT) were purchased from
Dharmacon (Lafayette, CO). Each gene was targeted with four
different sequences of siRNA directed against four different
regions of the cognate mRNA. Lithium chloride (LiCl) was
purchased from Sigma-Aldrich (France).
Transient transfections
To knockdown some of the Wnt/b-catenin pathway molecules
(LRP6, b-catenin, LEF1 and TCF-4) transient transfections were
carried out using Lipofectamine 2000 transfection reagent
(Invitrogen). Briefly, 24 h before transfection, 3610
5 TPC-1 cells
were seeded in 6-well plates. Transfections were performed in
serum-free OPTI-MEM using a 50 nM siRNAs and 6 ml
Lipofectamine. Cells were incubated with transfectants for 48 h.
For promoter studies, transient transfection of plasmids was
carried out using the jetPEI
TM reagent (PolyPlus Transfection,
France) according to the manufacturer’s instructions. We used
3 mg of TTF-1-luc plasmids or 0.5 mg of TOP-Flash-luc or FOP-
Flash-luc. Twenty four hours after transfection, cells were exposed
to LiCl (10 mM) for 24 hours. After harvesting, cell extracts were
assayed for luciferase activity (Luciferase Assay System, Promega,
Charbonnieres, France) and luminescence was measured in a
Figure 4. LiCl transactivates TTF-1 promoter and induces b-catenin recruitment on TCF/LEF binding sites in TTF-1 promoter. A: TPC-1
cells were transfected with pSV0AL-A(delta)59 firefly luciferase reporter plasmids containing progressive deletions of the TTF-1 promoter fragments or
with TOP-Flash-Luc and FOP-Flash-Luc. Cells were incubated in the absence or the presence of 10 mM LiCl for 24 h then luciferase activity was
assessed. Results from three independent experiments displayed mean 6 SD. p value: significant change compared with cells transfected under
normoxia (Mann-Whitney U test). (B) TCF/LEF consensus sequences found in the TTF-1 promoter were localised by using the Genomatix software.
(C) TPC-1 cells were incubated with or without 10 mM LiCl. ChIP was performed 1 h and 4 h later. Real time RT-PCR was achieved using b-catenin
primers to detect the active promoter site between the two selected sites. p,0.05 and 0.01 and 0.001 significant change compared to control
(ANOVA; Bonferroni’s test). Columns, mean of at least three independent experiments; bars, SD.
doi:10.1371/journal.pone.0022280.g004
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France). The luciferase activity was normalized to the protein
levels (assessed by Micro BCA
TM Protein Assay Kit, Pierce,
Brebieres, France).
The same protocol was used for transient transfections with
dominant-negative expression vectors. TPC-1 cells were cotrans-
fected with 3 mg of TTF-1-luc-2.11 plasmid and 1 mg of dominant-
negative expression vectors. Results were expressed as percent of
transcriptional activity: [luciferase activity elicited by each
sample6100]/luciferase activity elicited by the TOP-Flash-Luc
plasmid alone or TTF-1 luc-2.11 alone].
Lithium treatment
To determine the effect of LiCl (an inhibitor of GSK-3b)o n
TTF-1 expression, kinetic studies were performed on TPC-1. Cells
were plated in 6-well plates at 3610
4cells/well and incubated with
different LiCl concentrations (0, 5, 10, 20 mM) for 10 min, 24 h
and 48 h. qRT-PCR and Western Blot were performed after
harvesting the cells.
Real time PCR (qRT-PCR)
Total RNA was extracted from TPC-1 cells using RNeasy mini-
kit (Qiagen, Courtaboeuf, France). First-strand cDNA was
generated with M-MLV RT buffer pack (Promega France,
Charbonnie `res-les-Bains, France).
Primers used for Real-time PCR (qRT-PCR) are described in
Table 1. qRT-PCR was carried out with the ABI PRISM 7000
Taqman (Applied Biosystems, Perkin-Elmer) using SYBR Green-
ER qPCR Supermix for ABI PRISM (Invitrogen) according to
manufacturer’s instructions. All PCRs were performed in
duplicate. Gene regulation was determined by the 2
2DDCt method
[44] and normalized or compared to RPL13A (ribosomal protein)
levels [41]. For mRNA relative expression of TTF-1 and of Wnt/
b-catenin components, results are given as relative fold compared
to RPL13A. For knockdown experiments results are given as
relative fold compared to the non targeting siRNA (siNT). For
LiCl experiments results are given as relative fold compared to
untreated cells.
Protein extraction and Western blot analysis
Total protein extracts were obtained using M-PER reagent
(Pierce) with protease inhibitors cocktail (Roche, Neuilly, France).
Proteins were titrated by the BCA method using the BCA protein
assay (Thermo Scientific/Pierce, Courtaboeuf, France). Cell
extracts were separated on 10% SDS-PAGE gel. Proteins were
transferred using the iBlot
TM Dry Blotting System (Invitrogen) on
pre-cut nitrocellulose membranes, then blocked with 0.2% casein
(I-Block reagent; Tropix, Bedford, MA) in PBS with 0.1% Tween-
20. The membranes were incubated overnight at 4uC with the
primary antibody specific for TTF-1 (Upstate Cell Signaling,
1:300; Danvers, MA USA), b-catenin (rabbit polyclonal, 1:2000,
Sigma-Aldrich Chimie S.a.r.l. Lyon, France) or b-actin (rabbit
polyclonal, 1:1000, Sigma-Aldrich) used as internal control. Blots
were washed and incubated with anti-rabbit antibody conjugated
to alkaline phosphatase (1:20,000, Tropix) for 1H at room
temperature, and subsequently washed and revealed using CDP
Star chemoluminescence reagent (Perkin Elmer).
Real-time chromatin immunoprecipitation (ChIP) assay
TPC-1 cells were plated in 10 cm plates (3610
6cells/plate) and
treated or not with LiCl for 1 h and 4 h then fixed with 1%
formaldehyde added to the medium for 10 min, scraped, and
collected by centrifugation. Cells were resuspended in 300 mlo f
lysis buffer (5 mM piperazine-N,N9-bis(2-ethanosulfonic acid)
(PIPES pH 8.0), 85 mM KCl, 0.5% NP-40) with a cocktail of
protease inhibitors (Roche). Cells were pelleted by centrifugation
and suspended in 300 ml of 1% SDS, 10 mM EDTA, and 50 mM
Tris-HCl (pH 8.0) containing protease inhibitors. After incubation
on ice for 10 min, they were sonicated six times for 30 seconds
using Bioruptor (Diagenode). Lysates were then cleared by
centrifugation and the concentration of DNA was determined.
Equal amounts of DNA were diluted ten times in dilution-buffer
(0.01% SDS, 1% Triton X-100, 1.2 mM EDTA, 16.7 mM Tris-
HCl (pH 8.1), 167 mM NaCl). The chromatin solution was
precleared for one hour at 4uC on Protein G-Agarose/Salmon
Sperm DNA beads from Upstate. After brief centrifugation and
removal of the beads, DNA was incubated overnight at 4uCo na
rotating wheel with 1 mg of either anti-b-catenin, 2206, Sigma) or
non-relevant antibody (anti-nucleolin C23, SC-13057, Santa Cruz
biotechnology). Immune complexes were collected on Protein G-
Agarose/Salmon Sperm DNA beads from Upstate. Beads were
washed sequentially in TSE (0.1% SDS, 1% Triton X-100, 2 mM
EDTA, 20 mM Tris-HCl (pH 8.1), with 150 mM NaCl, TSE with
500 mM NaCl, buffer A (0.25 M LiCl, 1% NP-40, 1%
Table 1. Primers sequences used for real time-RT-PCR
analysis.
Gene
name Primer sequence Position
Length
(bp) Tm (6C)
WNT1 F:CTCTCTTCTTCCCCTTTGTC 1685–2029 345 59uC
R:AACTCGTGGCTCTGTATCC
WNT2B F:GATGGGACAAAGATGAATGG 1647–1928 282 55uC
R:GGCAGCAAGTAAGCAAAAG
DKK1 F:GAGTCCTTCTTCTGAGATGATGG 142–404 263 61uC
R:GGTACGGCTGGTAGTTGTC
LRP5 F:GTGTGTGACAGCGACTACAG 4714–4890 177 60uC
R:CGGGAAGAGATGGAAGTAG
LRP6 F:CAGGGTGGAATGAATGTGC 2740–2963 224 58uC
R:GTGGATGGGAAGGATGATG
Dsh1 F:TCAACGGAAGGGTGGTATC 1373–1665 293 62uC
R:GGCTGCTGGACACATTAGG
Dsh2 F:AACCCCTGCGAGTTCTTC 337–525 189 60uC
R:ATCCCCACCAGACACAAG
Dsh3 F:CCTCCATCACCAGTTCCAC 1234–1420 187 59uC
R:AGCCAGTCCACCACATCTG
b-catenin F:AAAATGGCAGTGCGTTTAG 1076–1175 99 56uC
R:TTTGAAGGCAGTCTGTCGTA
LEF1 F:CCTGGTCCCCACACAACTG 1405–1535 131 58uC
R:GGCTCCTGCTCCTTTCTCTG
TCF1 F:GACATCAGCCAGAAGCAAG 725–866 142 58uC
R:CACCAGAACCTAGCATCAAG
TCF3 F:GTACCCCTTCCTGATGATCC 437–580 144 60uC
R:GACCTCGTGTCCTTGACTG
TCF4 R:CCACATCATACGCTACACAC 913–1119 207 55uC
F:GACCTTTGCTCTCATTTCC
TTF-1 F:CCAGAACCACCGCTACAA 627–805 179 62uC
R:GTTTGCCGTCTTTCACCA
F=forward primer, R=reverse primer.
doi:10.1371/journal.pone.0022280.t001
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twice with Tris-EDTA and then eluted with 200 ml 1% SDS and
0.1 M NaHCO3. Cross-links were reversed by heating at 65uC for
4 h after adding NaCl to 200 mM final concentration. After
treatment with Proteinase K (50 mg/ml) for 1 h at 37uC, DNA was
purified using Geneclean Turbo kit (Q-Biogene). Next, real-time
PCR analysis of inputs and immunoprecipitated DNA samples
were performed using the following primers: P1F: CCCT-
CTTCCTCCTAAGCAGTTTC, P1R: TTAAAGTGGTG-
GCGTAAATGGC. P2F CCCAACTCTTCCTTTTACTCAG,
P2R: GTCACCCAGCTTCTTTCTCTC. Data are compared to
input and normalized to anti-nucleolin C23 and expressed as
2
2DDCt to determine the assay site IP-fold enrichment. The results
are given as relative fold in site occupancy compared with cells
cultured without LiCl.
Statistical analysis
Data are represented as mean 6 SD. Mann-Whitney U test was
used to compare the mean of Wnt compounds mRNA relative
levels after transfection with siRNAs and the mean of transcrip-
tional activity after transfection with plasmids. For all other
studies, means of treatment groups were compared with one-way
ANOVA. When the ANOVA showed that there were significant
differences between the groups, Dunnett’s test or Bonferroni’s test
was used to identify the sources of these differences. p#0.05 was
considered statistically significant.
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